About 1 in 10 Chronic Opioid Patients Tested Positive for THC

Of 244 urine drug screens from patients receiving chronic opioid therapy for pain at a single academic center (2024), 24 (9.8%) tested positive for THC. Provider responses to positive results varied widely: some documented patient counseling, others did not acknowledge the result. In a small subset, positive THC led to opioid therapy changes including tapering or discontinuation.

Retrospective review of 244 urine drug screen results from chronic opioid therapy patients at a single academic institution (January-December 2024). Assessed THC positivity prevalence and documented provider responses.

Nearly 10% of chronic opioid patients are concurrently using cannabis, often without their provider's knowledge. The inconsistent clinical response to positive THC screens highlights a need for standardized, non-punitive approaches to concurrent cannabis use in pain management.

As cannabis legalization expands, the intersection of cannabis use and opioid prescribing requires clearer clinical guidelines. Punitive responses (stopping opioids) may drive patients to hide cannabis use, while ignoring positive screens misses an opportunity for risk assessment.

Single institution with small sample. Retrospective review cannot capture provider reasoning. Cannot determine whether THC use was medical or recreational. 2024 data from a single year. Provider response documentation may not reflect actual conversations.